ICL to acquire a majority of Lavie Bio activity from Evogene.

ICL, a global specialty minerals and chemicals company, agreed to acquire a majority of Lavie Bio activity, an agricultural biologicals business, from Evogene, a computational biology company. Financial terms were not disclosed. "Today marks a significant milestone in Lavie Bio's journey," said Amit Noam, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world."